SkinHealth Systems (SKIN) Aktienübersicht
SkinHealth Systems Inc. ist ein globales Unternehmen für medizinische Ästhetik, das ein integriertes Ökosystem klinisch erprobter Lösungen in Nord- und Südamerika, im asiatisch-pazifischen Raum, in Europa, im Nahen Osten, in Afrika, Kanada und Lateinamerika anbietet. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
SKIN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SkinHealth Systems Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$0.66 |
| 52-Wochen-Hoch | US$2.69 |
| 52-Wochen-Tief | US$0.55 |
| Beta | 0.99 |
| 1 Monat Veränderung | -27.14% |
| 3 Monate Veränderung | 2.53% |
| 1 Jahr Veränderung | -69.72% |
| 3 Jahre Veränderung | -89.72% |
| 5 Jahre Veränderung | -96.94% |
| Veränderung seit IPO | -93.91% |
Aktuelle Nachrichten und Updates
Narrative-Update • Aug 07
SKIN: Fair Outlook Will Weigh Competitive Pressure Against New FDA Clearance
Analysts have trimmed their fair value estimate for SkinHealth Systems from about $1.00 to roughly $0.71 per share, citing updated models that factor in a higher discount rate, revised revenue growth and margin assumptions, as well as recent Street research pointing to competitive pressures in the lower priced segment of the aesthetics market. What’s in the News for SkinHealth Systems On May 8, 2026, SkinHealth Systems received a Nasdaq notice that its Class A common stock no longer met the Minimum Bid Price Requirement of at least $1.00 for 30 consecutive business days.Narrative-Update • Jul 10
SKIN: Fair Outlook Weighs Competitive Pressure Against New FDA Clearances
Analysts have trimmed their price target on SkinHealth Systems to $1.00 from $1.50, citing updated assumptions that reflect softer modeled revenue growth, a lower fair value estimate, modestly improved profit margin expectations, and a reduced future P/E multiple in light of ongoing competitive pressures in the lower end of the market. Analyst Commentary on SkinHealth Systems Recent research commentary on SkinHealth Systems points to a more cautious stance, with several bearish analysts revisiting their models after the latest quarterly update and trimming valuation assumptions to reflect ongoing competitive and execution risks.Recent updates
Narrative-Update • Aug 07
SKIN: Fair Outlook Will Weigh Competitive Pressure Against New FDA Clearance
Analysts have trimmed their fair value estimate for SkinHealth Systems from about $1.00 to roughly $0.71 per share, citing updated models that factor in a higher discount rate, revised revenue growth and margin assumptions, as well as recent Street research pointing to competitive pressures in the lower priced segment of the aesthetics market. What’s in the News for SkinHealth Systems On May 8, 2026, SkinHealth Systems received a Nasdaq notice that its Class A common stock no longer met the Minimum Bid Price Requirement of at least $1.00 for 30 consecutive business days.Narrative-Update • Jul 10
SKIN: Fair Outlook Weighs Competitive Pressure Against New FDA Clearances
Analysts have trimmed their price target on SkinHealth Systems to $1.00 from $1.50, citing updated assumptions that reflect softer modeled revenue growth, a lower fair value estimate, modestly improved profit margin expectations, and a reduced future P/E multiple in light of ongoing competitive pressures in the lower end of the market. Analyst Commentary on SkinHealth Systems Recent research commentary on SkinHealth Systems points to a more cautious stance, with several bearish analysts revisiting their models after the latest quarterly update and trimming valuation assumptions to reflect ongoing competitive and execution risks.
Narrative-Update • Jun 26
SKIN: Clearer Device Positioning And Margins Will Support Future Upside
Analysts have reduced the SkinHealth Systems price target to $2.00 from $3.50, citing updated models that reflect higher discount rates, softer revenue growth assumptions, lower expected profit margins, and a much higher projected future P/E multiple in light of rising competitive pressures across the beauty device market. Analyst Commentary Recent Street research on SkinHealth Systems highlights that analysts are recalibrating their expectations while still pointing to potential areas where the stock could regain investor interest.
Narrative-Update • Jun 06
SKIN: Future Returns Will Hinge On Delivering FY26 EBITDA Under Competitive Pressure
Narrative Update on SkinHealth Systems Analysts have trimmed the SkinHealth Systems price target from $2.50 to $2.00, citing updated models that factor in recent earnings, ongoing competitive pressure at the lower end of the market, and adjusted long term assumptions for revenue growth, profit margins, discount rate and future P/E. Analyst Commentary Recent research commentary around SkinHealth Systems centers on recalibrated price targets, revised models following quarterly updates, and an ongoing focus on how the company manages competitive pressure at the lower end of the market.Narrative-Update • Apr 21
SKIN: Future Returns Will Rely On FY26 EBITDA Delivery Despite Macro Pressures
Analysts trimmed Beauty Health's price target by $0.15 to $1.50, citing updated models after Q4 results where revenue was lower but ahead of expectations, FY26 EBITDA guidance points to upside versus current Street estimates, and softer near term distributor orders tied to macro pressure. Analyst Commentary Recent commentary highlights a mixed read on Beauty Health, with analysts weighing long term profit guidance against near term demand headwinds and a slightly lower price target of US$1.50.Narrative-Update • Apr 07
SKIN: Future Returns Will Be Supported By FY26 EBITDA Guidance Delivery
Analysts have trimmed Beauty Health's price target by $0.15 to $1.50 as they refresh models after Q4 results that showed revenue down but ahead of expectations, with updated EBITDA guidance for FY26 and softer near term distributor ordering under macro pressure helping to shape their outlook. Analyst Commentary Recent research paints a mixed picture for Beauty Health, with analysts updating models after Q4 and revisiting fair value as they factor in near term pressure on distributor orders alongside longer term profitability targets.Narrative-Update • Mar 24
SKIN: Future Returns Will Be Supported By FY26 EBITDA Upside Potential
The analyst price target for Beauty Health has been reduced by $0.15 to $1.50, as analysts factor in softer near term distributor ordering after Q4 revenue came in down but ahead of expectations, alongside FY26 EBITDA guidance that they view as implying roughly 20% upside versus the Street. Analyst Commentary Analysts are recalibrating their views on Beauty Health after the Q4 report, focusing on the tension between softer near term trends and what they see in the company’s longer term EBITDA guidance.Narrative-Update • Mar 10
SKIN: Updated Governance And Margin Execution Will Support Future Upside
Analysts have nudged their price target for Beauty Health higher to $3.50, citing slightly stronger assumptions around revenue growth, profit margins, and a modestly lower discount rate reflected in a small adjustment to the future P/E. Analyst Commentary Recent research points to a more constructive tone around Beauty Health, with price targets and ratings framed around what analysts see as the company’s ability to execute on its current plan rather than any major shift in its business model.Narrative-Update • Feb 24
SKIN: Higher Assumed P/E And Margin Execution Will Support Future Upside
Analysts have nudged their price targets on Beauty Health higher to $3.38, reflecting updated views on risk, modest revenue expectations, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Beauty Health has focused on how to balance risk, valuation, and execution, with some bullish analysts pointing to conditions they believe could support the higher US$3.38 price target.Analyseartikel • Feb 12
It's Down 30% But The Beauty Health Company (NASDAQ:SKIN) Could Be Riskier Than It Looks
The Beauty Health Company ( NASDAQ:SKIN ) shareholders won't be pleased to see that the share price has had a very...Narrative-Update • Feb 08
SKIN: Execution On Updated Margin Plan Will Support Future Upside
Analysts have nudged their price target on Beauty Health higher to around a fair value of US$3.38 per share, citing modest adjustments to growth, margins and future P/E assumptions reflected in recent TD Cowen and Jefferies research. Analyst Commentary Recent Street research around Beauty Health has centered on modestly higher valuation markers and a reaffirmation of a more wait and see stance on the shares.Analyseartikel • Feb 06
Is Beauty Health (NASDAQ:SKIN) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative-Update • Jan 25
SKIN: Improved Execution And Buyback Progress Will Support Future Upside
Analysts have inched their average price target for Beauty Health higher by US$0.15, reflecting updated views on growth, margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish analysts are framing the US$0.15 increase in the average price target as a sign that recent updates to growth and margin expectations still support the current valuation, even with a slightly lower assumed future P/E multiple.Narrative-Update • Jan 11
SKIN: Future Returns Will Be Supported By Stable Margins And Completed Buyback Program
Analysts have modestly adjusted their price target on Beauty Health, citing small tweaks to the discount rate, revenue growth expectations, profit margin assumptions and forward P/E multiples. Together, these changes support a refined valuation framework rather than a major reset in outlook.Narrative-Update • Dec 27
SKIN: Share Repurchase And New CEO Are Expected To Drive Upside
Analysts have modestly raised their price target on Beauty Health, reflecting a move in fair value from approximately 2.00 dollars to about 3.38 dollars. They factor in slightly stronger long term revenue growth expectations alongside a higher future earnings multiple, partially offset by a marginally lower projected profit margin and a slightly higher discount rate.Narrative-Update • Dec 13
SKIN: Future Returns Will Be Driven By Improved Device Churn Management
Analysts modestly raised their price target on Beauty Health to $2.50 from $2.00, citing early evidence that the CEO's reset is helping manage device churn, spur consumables innovation, and deepen engagement across its 35,000 strong installed base. Analyst Commentary Analysts are reacting to the updated outlook with a balanced tone, reflecting both improving fundamentals and lingering execution risks that cap near term upside.Narrative-Update • Nov 29
SKIN: Future Growth Will Be Driven By Improved Churn Management
Analysts have raised their price target for Beauty Health from $2.00 to $2.50. They cite improved management of device sales, consumables innovation, and deeper provider engagement as key factors supporting the company's outlook.Analyseartikel • Nov 27
Is There An Opportunity With The Beauty Health Company's (NASDAQ:SKIN) 35% Undervaluation?
Key Insights The projected fair value for Beauty Health is US$2.24 based on 2 Stage Free Cash Flow to Equity Current...Narrative-Update • Nov 15
SKIN: Future Revenue Will Be Driven By Improved Device Sales Management
Analysts have increased their price target for Beauty Health from $2.00 to $2.50. They cite improved device sales management, innovation in consumables, and deeper provider engagement as drivers for this positive outlook.Analyseartikel • Oct 14
The Market Doesn't Like What It Sees From The Beauty Health Company's (NASDAQ:SKIN) Revenues Yet As Shares Tumble 40%
The Beauty Health Company ( NASDAQ:SKIN ) shares have had a horrible month, losing 40% after a relatively good period...Narrative-Update • Sep 20
Premium Beauty Markets Will Face Risks And Rewards
Beauty Health’s consensus price target has increased notably as the market now assigns a higher future P/E multiple despite a slight decline in net profit margin, reflecting increased investor optimism and raising the fair value estimate from $1.88 to $2.17. What's in the News Completed repurchase of 10,350,749 shares (7.81%) for $30.18 million; no shares repurchased in the latest tranche.Analyseartikel • Aug 30
The Beauty Health Company's (NASDAQ:SKIN) 30% Price Boost Is Out Of Tune With Revenues
The The Beauty Health Company ( NASDAQ:SKIN ) share price has done very well over the last month, posting an excellent...Narrative-Update • Aug 08
Premium Beauty Markets Will Face Risks And Rewards
The upward revision in Beauty Health’s consensus price target to $1.75 is primarily driven by a substantial increase in revenue growth forecasts and a lower discount rate, signaling improved growth expectations and a more favorable risk profile. What's in the News Company updated earnings guidance, projecting Q3 net sales of $65–$70 million and full-year net sales of $285–$300 million, citing strong first half performance.Analyseartikel • May 11
Analysts Are Updating Their The Beauty Health Company (NASDAQ:SKIN) Estimates After Its First-Quarter Results
A week ago, The Beauty Health Company ( NASDAQ:SKIN ) came out with a strong set of first-quarter numbers that could...Analyseartikel • Apr 11
The Beauty Health Company (NASDAQ:SKIN) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, The Beauty Health Company ( NASDAQ:SKIN ) shares are down a considerable 26% in...
Neues Narrative • Apr 02
Sales Execution And Hydralock Booster Launch Will Strengthen Future Prospects
Operational improvements and strategic market positioning are set to enhance profitability and boost revenue growth.Analyseartikel • Mar 14
The Beauty Health Company (NASDAQ:SKIN) Analysts Just Cut Their EPS Forecasts Substantially
Market forces rained on the parade of The Beauty Health Company ( NASDAQ:SKIN ) shareholders today, when the analysts...Analyseartikel • Feb 27
Is Beauty Health (NASDAQ:SKIN) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 27
The Beauty Health Company (NASDAQ:SKIN) Doing What It Can To Lift Shares
The Beauty Health Company's ( NASDAQ:SKIN ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a buy right...Analyseartikel • Oct 18
Health Check: How Prudently Does Beauty Health (NASDAQ:SKIN) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Aktionärsrenditen
| SKIN | US Personal Products | US Markt | |
|---|---|---|---|
| 7D | -0.2% | 0.6% | 1.7% |
| 1Y | -69.7% | -12.7% | 20.0% |
Rendite im Vergleich zur Industrie: SKIN unter dem Niveau der Branche US Personal Products , die im vergangenen Jahr eine Rendite von -12.7% erzielte.
Rendite vs. Markt: SKIN hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20 erzielte.
Preisvolatilität
| SKIN volatility | |
|---|---|
| SKIN Average Weekly Movement | 19.0% |
| Personal Products Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von SKIN war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: SKINDie wöchentliche Volatilität (19%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1997 | 613 | Pedro Malha | www.skinhealthsystems.com |
SkinHealth Systems Inc. ist ein globales Unternehmen für medizinische Ästhetik, das ein integriertes Ökosystem klinisch erprobter Lösungen in Nord- und Südamerika, im asiatisch-pazifischen Raum, in Europa, im Nahen Osten, in Afrika, Kanada und Lateinamerika anbietet. Das Vorzeigeprodukt des Unternehmens ist HydraFacial, das die Haut mit proprietären Lösungen und Seren reinigt, extrahiert und mit Feuchtigkeit versorgt. Darüber hinaus bietet es Syndeo-Geräte an, bei denen es sich um Verabreichungssysteme handelt, die darauf ausgelegt sind, Anbieter mit den Präferenzen der Verbraucher zu verbinden, um ein persönlicheres Erlebnis zu schaffen; Verbrauchsmaterialien wie Einwegspitzen, Lösungen und Seren, die für eine Hydrafacial-Behandlung verwendet werden; SkinStylus SteriLock Microsystem, ein Mikroneedling- und Nanoneedling-Gerät, das zur Behandlung von chirurgischen oder traumatischen hypertrophen Narben am Bauch und Aknenarben im Gesicht bei den Fitzpatrick-Hauttypen I, II und III eingesetzt wird, sowie Keravive-Peptidlösungen und Peptidsprays zum Mitnehmen für die Behandlung von Kopfhauterkrankungen.
SkinHealth Systems Inc.'s Grundlagenzusammenfassung
| SKIN grundlegende Statistiken | |
|---|---|
| Marktanteil | US$86.99m |
| Gewinn(TTM) | -US$28.43m |
| Umsatz(TTM) | US$290.05m |
0.3x
Kurs-Umsatz-Verhältnis-3.0x
Kurs-Gewinn-Verhältnis Ist SKIN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| SKIN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$290.05m |
| Kosten der Einnahmen | US$97.60m |
| Bruttogewinn | US$192.45m |
| Sonstige Ausgaben | US$220.88m |
| Gewinn | -US$28.43m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.22 |
| Bruttomarge | 66.35% |
| Nettogewinnspanne | -9.80% |
| Schulden/Eigenkapital-Verhältnis | 621.2% |
Wie hat sich SKIN auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/14 20:26 |
| Aktienkurs zum Tagesende | 2026/08/13 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
SkinHealth Systems Inc. wird von 11 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Bruce Jackson | Benchmark Company |
| Navann Ty Dietschi | BNP Paribas |
| Susan Anderson | Canaccord Genuity |